XNAS
HEPA
Market cap954kUSD
Jun 20, Last price
0.08USD
1D
-9.09%
1Q
-90.00%
Jan 2017
-99.99%
IPO
-99.98%
Name
Contravir Pharmaceuticals Inc
Chart & Performance
P/E
—
P/S
—
EPS
—
Div Yield, %
—
Shrs. gr., 5y
3.76%
Rev. gr., 5y
%
Revenues
0k
Net income
-13m
L-73.04%
CFO
-18m
L-55.45%
Earnings
Aug 11, 2025
Profile
Hepion Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development of drug therapy treatment for chronic liver diseases in the United States. It is involved in developing Rencofilstat, a cyclophilin inhibitor that has completed Phase 2a clinical trials to target multiple pathologic pathways involved in the progression of liver disease; and is in clinical-phase development for the treatment of non-alcoholic steatohepatitis (NASH), as well as in nonclinical studies to reduce liver fibrosis and hepatocellular carcinoma tumor burden in experimental models of NASH, and has demonstrated antiviral activities towards hepatitis B, C, and D viruses through several mechanisms. The company was formerly known as ContraVir Pharmaceuticals, Inc. and changed its name to Hepion Pharmaceuticals, Inc. in July 2019. Hepion Pharmaceuticals, Inc. was incorporated in 2013 and is headquartered in Edison, New Jersey.
Valuation
Title USD in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2024‑12 | 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2017‑06 | 2016‑06 | 2015‑06 | |
| Income | |||||||||||
Revenues | |||||||||||
Cost of revenue | 19,347 | 45,325 | 43,695 | ||||||||
Unusual Expense (Income) | |||||||||||
NOPBT | (19,347) | (45,325) | (43,695) | ||||||||
NOPBT Margin | |||||||||||
Operating Taxes | 2,969 | 409 | (2,884) | ||||||||
Tax Rate | |||||||||||
NOPAT | (22,316) | (45,734) | (40,811) | ||||||||
Net income | (13,192) -73.04% | (48,926) 15.94% | (42,200) 28.96% | ||||||||
Dividends | |||||||||||
Dividend yield | |||||||||||
Proceeds from repurchase of equity | 4,495 | (3,138) | |||||||||
BB yield | |||||||||||
| Debt | |||||||||||
Debt current | 2,900 | 232 | 54 | ||||||||
Long-term debt | 302 | 54 | |||||||||
Deferred revenue | |||||||||||
Other long-term liabilities | 333 | 5,430 | 2,094 | ||||||||
Net debt | 2,494 | (14,252) | (50,517) | ||||||||
| Cash flow | |||||||||||
Cash from operating activities | (18,216) | (40,889) | (34,961) | ||||||||
CAPEX | (14) | (16) | |||||||||
Cash from investing activities | (600) | (14) | (14) | ||||||||
Cash from financing activities | 4,350 | 4,495 | (5,138) | ||||||||
FCF | (23,037) | (45,844) | (40,487) | ||||||||
| Balance | |||||||||||
Cash | 406 | 14,786 | 51,189 | ||||||||
Long term investments | (565) | ||||||||||
Excess cash | 406 | 14,786 | 50,624 | ||||||||
Stockholders' equity | (236,956) | (223,011) | (174,088) | ||||||||
Invested Capital | 238,325 | 236,047 | 226,091 | ||||||||
ROIC | |||||||||||
ROCE | |||||||||||
| EV | |||||||||||
Common stock shares outstanding | 123 | 3,971 | 3,811 | ||||||||
Price | |||||||||||
Market cap | |||||||||||
EV | |||||||||||
EBITDA | (19,316) | (45,258) | (43,618) | ||||||||
EV/EBITDA | |||||||||||
Interest | 1,247 | 9 | 10 | ||||||||
Interest/NOPBT | |||||||||||